Resimac Group Limited (ASX:RMC)

Australia flag Australia · Delayed Price · Currency is AUD
0.8000
0.00 (0.00%)
Jul 17, 2026, 4:17 PM AEST
Market Cap316.23M -8.1%
Revenue (ttm)195.86M +46.8%
Net Income49.51M +77.7%
EPS0.12 +79.1%
Shares Out 395.28M
PE Ratio6.44
Forward PE6.16
Dividend0.07 (8.75%)
Ex-Dividend DateMar 6, 2026
Volume186,443
Open0.8000
Previous Close0.8000
Day's Range0.7850 - 0.8000
52-Week Range0.7850 - 1.2250
Beta1.39
AnalystsHold
Price Target0.90 (+12.5%)
Earnings DateAug 28, 2026

About Resimac Group

Resimac Group Limited provides residential mortgage and asset finance lending products in Australia and New Zealand. The company operates through Home Loan Lending business, New Zealand Lending, and Asset Finance Lending segments. It offers prime and specialist lending products; SME/commercial finance products; and home, equipment, secured, novated leasing, and car loans. It also provides mortgage originator and trustee, lender, mortgage manager and broker, consumer and commercial lending, managed investment trust, and LMI captive insurer servi... [Read more]

Sector Financials
Founded 1985
Employees 300
Stock Exchange Australian Securities Exchange
Ticker Symbol RMC
Full Company Profile

Financial Performance

In fiscal year 2025, Resimac Group's revenue was 163.59 million, an increase of 11.08% compared to the previous year's 147.27 million. Earnings were 34.58 million, a decrease of -0.02%.

Financial Statements

Analyst Summary

According to 2 analysts, the average rating for RMC stock is "Hold." The 12-month stock price target is $0.90, which is an increase of 12.50% from the latest price.

Price Target
$0.90
(12.50% upside)
Analyst Consensus: Hold
Stock Forecasts

News

Resimac Group Earnings Call Transcript: H1 2026

Strong earnings growth driven by higher lending volumes, improved margins, and disciplined cost and risk management. Home loans and asset finance portfolios expanded, with improved credit performance and reduced impairments. Capital returns to shareholders increased, and outlook remains positive despite expected headwinds from portfolio runoff and funding cost volatility.

5 months ago - Transcripts

Resimac Group Quarterly report: H1 2026

Resimac Group has published its H1 2026 quarterly earnings report on February 24, 2026.

5 months ago - Filings

Resimac Group Slides: H1 2026

Resimac Group has posted slides in relation to its H1 2026 quarterly earnings report, which was published on February 24, 2026.

5 months ago - Filings

Resimac Group Earnings release: H1 2026

Resimac Group released its H1 2026 earnings on February 24, 2026, summarizing the period's financial results.

5 months ago - Filings

Resimac Group Transcript: AGM 2025

The AGM highlighted strong financial growth, a special dividend, and successful integration of a major acquisition. Strategic focus is on digital transformation, AI, and operational efficiency, with all resolutions—including director re-elections—supported by a large majority.

8 months ago - Transcripts

Resimac Group Earnings Call Transcript: H2 2025

Strong FY25 results with 13% growth in normalised operating profit, AUM up to $15.9B, and a successful $1.5B auto portfolio acquisition. Higher impairments impacted net profit, but cost and margin management, plus technology investment, position the group for sustainable growth.

11 months ago - Transcripts

Resimac Group Annual report: H2 2025

Resimac Group has published its H2 2025 annual report on August 27, 2025.

11 months ago - Filings

Resimac Group Slides: H2 2025

Resimac Group has posted slides in relation to its H2 2025 quarterly earnings report, which was published on August 27, 2025.

11 months ago - Filings

Resimac Group Earnings release: H2 2025

Resimac Group released its H2 2025 earnings on August 27, 2025, summarizing the period's financial results.

11 months ago - Filings

ASX 200 LIVE: Mayne Pharma shares plunge; CBA hits record; JHX sales, earnings slip amid AZEK buy; ASIC sues Resimac, sharemarket rises

Shares lift; CBA resets intraday record, tops $176; Mayne Pharma-Cosette tie-up hangs in balance; Nufarm plunges; James Hardie drops 5pc. Follow live.

1 year ago - The Australian Financial Review